Inside Australia's Government-Funded Medical Cannabis Research Push

Photo by Yaroslav Shuraev via Pexels.

Ten years ago, growing cannabis for anything other than industrial hemp fibre was a federal offence in Australia. Today the country authorises close to a million prescription applications a year for it. The pivot point was 2015, when the federal government passed legislation permitting cultivation of cannabis for medical and scientific purposes for the first time in the country's history. A year later, amendments to the Therapeutic Goods Act opened a prescribing pathway, letting doctors access cannabis as an unapproved medicine through special access provisions. What followed wasn't just a commercial gold rush, though there's been plenty of that too. Australia did something fairly unusual among nations that have loosened cannabis law: it built a deliberate, publicly funded research apparatus around the plant, wiring universities, medical research institutes and state health departments into the system from the start rather than leaving the science to whichever private companies could afford to run trials. That infrastructure has now had the better part of a decade to produce results. The prescribing side of the ledger tells one story -- 979,000 applications authorised in 2024 alone. The research side tells a much narrower one: only two cannabis-derived products have ever made it through full registration with Australia's therapeutic goods regulator. That gap between a booming access market and a thin shelf of proven medicines is now the subject of a formal regulatory review, and it's worth understanding how the country got here before looking at where it's headed.

The Legal Foundation: From Cultivation Ban to Clinical Pathway

Photo by Mark Direen via Pexels.

Australia's cannabis reform didn't happen in one motion -- it happened in two, and the sequencing matters more than people usually give it credit for. The 2015 legislation, amendments to the Narcotic Drugs Act 1967, dealt exclusively with supply: for the first time, growers and manufacturers could legally cultivate cannabis and process it into medicine, provided they held the right federal licence. That law said nothing about who could receive that medicine or how. The second piece came in 2016, when changes to the Therapeutic Goods Act gave doctors a legal route to prescribe cannabis products that hadn't gone through standard TGA approval, using the existing Special Access Scheme and, later, the Authorised Prescriber pathway.

ACRE: Australia's First Federally Funded Cannabinoid Research Centre

Photo by Artem Podrez via Pexels.

Most countries that have relaxed cannabis law have leaned on private capital to fund whatever science eventually gets done -- companies running their own trials to support their own product registrations, if they bother at all. Australia took a different route almost immediately. In 2017, the National Health and Medical Research Council -- the country's main public funder of health research -- established the Australian Centre for Cannabinoid Clinical and Research Excellence, known as ACRE, through its Centre of Research Excellence scheme. It's based at the University of Newcastle, which gave the project an academic home rather than a corporate one from day one.

Beyond ACRE: Philanthropy and State-Federal Co-Investment

Photo by Jakub Zerdzicki via Pexels.

Public funding didn't stop at ACRE, and this is where Australia's approach starts to look genuinely layered rather than just well-intentioned. The largest single push came from private philanthropy: Barry and Joy Lambert, a banking-industry couple whose granddaughter has severe epilepsy, donated $33.7 million to the University of Sydney to establish the Lambert Initiative for Cannabinoid Therapeutics -- one of the biggest single gifts to cannabis research anywhere in the world, comparable in scale to endowed cannabinoid research programs in the United States and Israel.

What All This Funding Has Actually Produced

Photo by cottonbro studio via Pexels.

Here's the uncomfortable number at the centre of Australia's cannabis story: after roughly a decade of public and philanthropic research investment, exactly two cannabis-derived medicines sit on the Australian Register of Therapeutic Goods with full approval. One is Epidyolex, a purified CBD formulation approved for certain severe epilepsy syndromes including Lennox-Gastaut and Dravet syndrome. The other is Sativex, a nabiximols oral spray approved for spasticity associated with multiple sclerosis. Both went through the standard TGA registration pathway, meaning they cleared the same evidentiary bar as any other prescription pharmaceutical -- randomised trials, dose-response data, manufacturing quality standards, the whole apparatus.

The Numbers Behind the Boom

The scale of what's actually moving through Australia's medical cannabis system is worth sitting with for a moment. In 2024, the Therapeutic Goods Administration authorised 979,000 prescription applications through its specialised access pathways -- the Special Access Scheme and the Authorised Prescriber scheme -- for products that, as covered above, are almost entirely unregistered medicines. That's not a rounding error in a niche therapeutic category; it's close to a million approvals in a country of roughly 27 million people.

Regulators Push Back: The 2025 Reckoning

Photo by Nataliya Vaitkevich via Pexels.

All of that growth has finally drawn a formal regulatory response. In 2025 the TGA opened a public consultation into the safety and regulatory oversight of unapproved cannabis products, with submissions due by 7 October 2025. The stated trigger was safety: regulators have been watching products with higher THC concentrations move through special access pathways at volumes and speeds that weren't really anticipated when the special access framework was built for individual compassionate cases rather than mass prescribing.

Step back from the individual numbers and the shape of Australia's experiment becomes clear. Public research infrastructure and a fast-scaling prescription market can absolutely grow side by side -- Australia is proof of that. What the country's decade of reform also shows is that they don't grow at the same speed, or answer to the same clock. The research apparatus, built through the NHMRC, the Lambert Initiative, state health departments and CRC co-investment, has produced exactly two medicines that meet the conventional evidentiary bar for a registered pharmaceutical. The access apparatus, built on special access provisions never designed for this kind of volume, has produced nearly a million authorised prescriptions in a single year. Both are real accomplishments. Neither was built to match the other's pace, and that mismatch is precisely what the TGA's 2025-26 reviews are now trying to resolve.

What comes out of those reviews will likely determine whether Australia's next decade of cannabis policy is about reconciling access with evidence, or simply picking one to prioritise over the other. Tightening special access too abruptly risks cutting off patients who've come to rely on products that, however loosely vetted, are legally and reliably available to them. Leaving the system as-is risks normalising a permanent two-tier structure where a tiny fraction of the market runs on trial data and the overwhelming majority runs on prescriber discretion and manufacturer claims. Other countries watching from the outside -- and plenty are, given how few nations have tried anything like Australia's publicly funded model -- should take two lessons from this. The funding architecture worked: philanthropic, state and federal money can genuinely build durable cannabinoid science infrastructure rather than leaving it to industry. But the oversight architecture that was supposed to keep pace with a scaling market didn't, and Australia is now rebuilding it in real time, under public scrutiny, with patients already depending on the system it's trying to fix.